Macfarlanes advises Sterling Pharma Solutions on the funding for its acquisition of US specialist manufacturing facility

07 October 2020

Macfarlanes has advised global biopharmaceutical contract development and manufacturing organisation Sterling Pharma Solutions on the equity and debt funding for its acquisition of Alcami’s Germantown facility in the US.

The acquisition will facilitate a larger US presence for Sterling Pharma Solutions and will provide additional capacity for development and manufacturing projects, specifically those with complex and hazardous requirements. 

 The Germantown facility houses state-of-the-art development, scale-up and manufacturing facilities and has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.

The Macfarlanes team for this matter was led by corporate and M&A partner Alex Edmondson with assistance from senior solicitor Felicity Powell and finance solicitor Owen Giles.

Alex Edmondson comments: “We are pleased to have acted for Sterling Pharma Solutions in relation to the acquisition of a facility which will support their growth strategy in the US market.”